Evidence map›Paper›PMID 39289512›Full record

ArticleScientific reports2024

Enhanced efficacy of combined VEGFR peptide-drug conjugate and anti-PD-1 antibody in treating hepatocellular carcinoma.

Jiacheng Liu, Yaowei Bai, Xiaoming Liu, Binqian Zhou, Peng Sun, Yingliang Wang, Shuguang Ju, Chen Zhou, Chaoyang Wang, Wei Yao and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jiacheng Liu *Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China.
Yaowei Bai *Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China.
Xiaoming Liu *Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China.
Binqian ZhouDepartment of Ultrasound, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430014, China.
Peng SunMSC Clinical & Technical Solutions, Philips Healthcare, Wuhan, China.
Yingliang WangDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China.
Shuguang JuDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China.
Chen ZhouDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China.
Chaoyang WangDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China.
Wei YaoDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China.
Huihui YangWuhan Institute of Shipbuilding Technology, Hubei, 435003, China.
Xin JiangHospital of Honghe State affiliated to Kunming Medical University, Kunming, China.
Lian YangDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China. yanglian@hust.edu.cn.
Dongyuan WangDepartment of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. wangdy2019@hust.edu.cn.
Chuansheng ZhengDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China. hqzcsxh@sina.com.

Funding

National Natural Science Foundation of China 22007033National Natural Science Foundation of China 81873919Shenzhen High-tech Zone Development Special Plan Pingshan District Innovation Platform Construction Project 29853MKCJ202300208Wuhan Science and Technology Bureau of Hubei Province of China 2023020201020236
6 · The paper itself

Abstract

This study aimed to design a VEGFR-targeting peptide-drug conjugate with the ability to decrease tumor burden and suppress tumor angiogenesis, and to further evaluate the therapeutic effect of anti-PD-1 antibody in HCC therapy. A VEGFR-targeting peptide VEGF

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsProgrammed Cell Death 1 ReceptorAnimalsCell Line, TumorCell ProliferationHumansImmunoconjugatesMiceNeovascularization, PathologicPeptidesReceptors, Vascular Endothelial Growth FactorVascular Endothelial Growth Factor AImmunoconjugatesPeptidesProgrammed Cell Death 1 ReceptorReceptors, Vascular Endothelial Growth FactorVascular Endothelial Growth Factor AAngiogenesisanti-PD-1 antibodyPeptide–drug conjugateTumor burdenTumor vascular normalization

Identifiers

PMID39289512
PMCPMC11408695

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.